The identification, purification and characterization of cancer stem cells (CSCs) 
Introduction

Cancer is the second deadliest disease in the United
. Discovered initially in leukaemia [2] , cancer stem cell populations have been isolated from several tissues, including breast, brain and colorectal cancers [3] [4] [5] . The [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] , ovarian cancer [33] [34] [35] , colon cancer [36, 37] , prostate cancer [14, [38] [39] [40] [41] [42] [43] and brain cancer [44, 45] 
Molecular profiling of brain cancer stem cells
Brain cancer is a highly heterogeneous disease consisting of multiple tumour types affecting both children and adults [57] . [76] .
Application of inhibitors of endothelial cells significantly depleted tumour blood vessels resulting in a dramatic reduction of tumour stem cells but not CD 133 -cells in the bulk tumour. This suggests that targeting the unique vulnerabilities of tumour stem cell populations should include further characterization of the micro-environment that support and sustains tumour stem cell selfrenewal and differentiation. Large-scale molecular profiling of purified sub-populations of tumour cells from GBM will play a critical role in further defining
these molecular targets [77] . (Fig. 1) . [81] 
Molecular profiling of breast cancer stem cells
CSCs have also been identified and characterized for breast tumours, a much more common malignancy than brain tumours. Breast cancer tumours contain a sub-population of highly tumourigenic cells characterized by CD44 expression and no or low
Isobaric tagging for relative and absolute quantitation (iTRAQ)
Stable isotope labelling enables the quantitative analysis of protein concentrations through mass spectrometry (MS). One state-of-the-art technique for quantitative MS is iTRAQ
Biomolecular networks in cancer
Systems approaches to cancer [95] [96] [97] [98] [99] [102] and even to predict treatment response [103, 104] [106] . These successes with model organisms have also been extended to models of simple human systems such as the erythrocyte [107, 108] and mitochondria [109] Computational modelling and systems approaches will be key to catalyzing the future of drug discovery [117, 118] 
